KMT2A and acute myeloid leukemia: For example, approximately 2%–9% of patients treated with etoposide develop acute myeloid leukemia (t‐AML) (Winick et al. 1993), which is associated with translocations involving the MLL (KMT2A) gene located at 11q23 and multiple fusion partner genes, such as ENL, AF4, AF6, and AF9 (Felix 1998; Cowell et al. 2012).